On September 24, 2026, researchers introduced Shielded Bitcoin, a proposal to improve Bitcoin transaction privacy without altering its core protocol. The system uses encrypted notes, nullifiers, and zero-knowledge proofs to hide sender, recipient, and amounts, while keeping Bitcoin's consensus rules intact. It operates as a metaprotocol, meaning Bitcoin nodes do not verify the privacy features, relying instead on separate software. While promising, Shielded Bitcoin is still a draft with no implementation, facing challenges like higher fees, limited anonymity sets, and regulatory transparency requirements. Investors should meanwhile manage their own privacy by avoiding address reuse and carefully controlling wallet keys and records.
Shielded Bitcoin privacy on L1 is the subject, with Pluang market data providing context. As of Sep 26, 2026 09:31 WIB, 43 of 50 major cryptocurrencies on Pluang rose while 6 fell. EGLD was priced at Rp82.675 with a 1-day change of +4.64%, ADA at Rp4.678 with +4.63%, and SAND at Rp814 with +4.27%.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
